Quanterix's ultra-sensitive Simoa technology is utilized heavily in research and clinical studies targeting neurology, oncology, immunology, infectious diseases, and cardiology. The company's biomarker detection platforms play a particularly vital role in advancing diagnostics and therapeutics for neurodegenerative conditions—such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury—by enabling the precise measurement of low-abundance proteins like neurofilament light chain years before traditional clinical symptoms manifest.